SCHEMBL17908994

SCHEMBL17908994

CCCOC(=O)CCCOCCOCCOCCOCC(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 1/20 0.46
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ DNM1 Q05193 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ PRKCA P17252 1/20 0.36
▸ PRKCE Q02156 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17909645 1.00 DGKA (0.46) DGKAMAPTLMNAALDH1A1CYP3A4
SCHEMBL17909641 1.00 DGKA (0.46) DGKAMAPTLMNAALDH1A1CYP3A4
SCHEMBL17908728 0.92 DGKA (0.49) DGKAMAPTLMNAALDH1A1CYP3A4
SCHEMBL17908808 0.92 DGKA (0.49) DGKAMAPTLMNAALDH1A1CYP3A4
SCHEMBL17909393 0.92 DGKA (0.49) DGKAMAPTLMNAALDH1A1CYP3A4
SCHEMBL17909228 0.90 DGKA (0.51) DGKAMAPTLMNAALDH1A1DNM1
SCHEMBL17908820 0.90 DGKA (0.51) DGKAMAPTLMNAALDH1A1DNM1
SCHEMBL17909328 0.90 DGKA (0.51) DGKAMAPTLMNAALDH1A1DNM1
SCHEMBL17909733 0.89 DGKA (0.54) DGKAMAPTLMNAALDH1A1DNM1
SCHEMBL17908807 0.89 DGKA (0.54) DGKAMAPTLMNAALDH1A1DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3048093-B1 ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF MORESCO CORP (JP) 2019-02-20 — — EP disclosed
US-10077229-B2 Ether-containing monoester compound and use thereof MORESCO CORPORATION (JP) 2018-09-18 — — US disclosed
EP-3048093-A1 ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF Moresco Corporation (JP) 2016-07-27 — — EP disclosed
US-20160200998-A1 ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF MORESCO CORPORATION (JP) 2016-07-14 — — US disclosed
CN-105579431-A Ether-containing monoester compound and use thereof MORESCO CORP 2016-05-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077229-B2 Ether-containing monoester compound and use thereof SFN, CCNE2, HSD3B2 DGKA 1202/4885MAPT 3437/4885LMNA 3897/4885
US-20160200998-A1 ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF SFN, CCNE2, MSMO1 DGKA 1333/4885MAPT 3717/4885LMNA 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback